This book provides a comprehensive overview of the clinical challenges faced during the treatment of patients with cardiorenal syndrome (CRS). The bidirectional link that associates renal and cardiovascular diseases means that patients with CRS have an increased risk of hospital admission and mortality as a result of their coexistence yet, there are no agreed guidelines for their management. Cardio-Renal Clinical Challenges takes clinical presentations and clinical problems as its base, and the…
This book provides a comprehensive and systematic review of the latest findings in a wide spectrum of clinically important aspects of chronic kidney disease (CKD), focusing on clinical diagnosis and therapeutics. CKD is a global health problem with a rising morbidity and mortality. The last decade has seen significant improvements in determining the incidence, prevalence, and complications of CKD, mainly thanks to the definitions of CKD developed by the National Kidney Foundation’s Kidney Disea…
Dyslipidemia in chronic kidney disease is a common clinical problem and growing in prevalence. With the recent publication of clinical practice guidelines on the management of lipid related disorders in patients affected by chronic kidney disease, an up-to-date and comprehensive resource of evidence-based literature is needed. Dyslipidemias in Kidney Disease captures the growing body of information on this subject matter. This book presentsthe latest clinical evidence and management guidance fo…
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully …
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. How to take and store this medicine and possible side effects to watch for are reviewed.
This book is the first title that focuses exclusively on kidney disease and its impact in the cardiac catheterization laboratory. The increasing prevalence of vascular risk factors such as diabetes, obesity and hypertension coupled with increased longevity has resulted in a worldwide epidemic of cardiovascular and chronic kidney disease (CKD). Never has the impact of one organ system on the other been so profound, as in the current context of cardio-renal interactions. The cross talk between th…
Chronic Kidney Disease (CKD) is a recognized risk factor for cardiovascular events and death. The coexistence of CKD and heart failure is increasing in prevalence worldwide and requires a unique and subtle approach to patient management. The Kidney in Heart Failure focuses on the changes that occur in kidney physiology as a function of a failing heart. This comprehensive resource covers epidemiology, pathophysiology, management of kidney disorders and advances in nephropathy management. In add…
The presence of Chronic Kidney Disease (CKD) increases the risk of death from cardiovascular causes and makes the management of heart failure difficult. The coexistence of CKD and heart failure is increasing in prevalence worldwide and requires a unique and subtle approach to patient management. Managing the Kidney in Heart Failure focuses on the therapeutic management of cardio renal patients. Common heart and kidney failure conditions are presented along with treatment scenarios aimed to red…
Your red blood cells need iron to help carry oxygen through your body. Many people with chronic kidney disease (CKD) have anemia (not enough red blood cells or hemoglobin in the blood). Oral irons, such as ferrous sulfate, ferrous gluconate, ferrous fumarate, and FeraMAX® 150, will give you enough iron to make make hemoglobin. This will make sure your body gets enough oxygen. How to take and store these medicines, and what side effects to watch for are reviewed.
This concise book provides practical strategies to help nephrologists and endocrinologists correctly diagnose and treat the various forms of parathyroid disease they may encounter in the management of chronic kidney disease. Each chapter deals with various topics related to parathyroid gland anatomy and physiology, as well as diagnostic tests and their particularities in regard to chronic disease. The book highlights the range of therapies used for the treatment of secondary hyperparathyroidism…